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RESEARCH ARTICLE
APNG as a prognostic marker in patients with
glioblastoma
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Helene Derand4, Jesper Lohse4, Mia D. Sørensen1,2, Steinbjørn Hansen2,3, Bjarne
W. Kristensen1,2*
1 Department of Pathology, Odense University Hospital, Odense, Denmark, 2 Department of Clinical
Research, University of Southern Denmark, Odense, Denmark, 3 Department of Oncology, Odense




Expression of the base excision repair enzyme alkylpurine-DNA-N-glycosylase (APNG)
has been correlated to temozolomide resistance. Our aim was to evaluate the prognostic
value of APNG in a population-based cohort with 242 gliomas including 185 glioblastomas
(GBMs). Cellular heterogeneity of GBMs was taken into account by excluding APNG
expression in non-tumor cells from the analysis.
Methods
APNG expression was evaluated using automated image analysis and a novel quantitative
immunohistochemical (IHC) assay (qIHC), where APNG protein expression was evaluated
through countable dots. Non-tumor cells were excluded using an IHC/qIHC double-staining.
For verification, APNG was measured by a quantitative double-immunofluorescence (IF)
assay. As validation APNG mRNA expression was evaluated using independent TCGA
data.
Results
Using qIHC, high levels of APNG were associated with better overall survival (OS) in univari-
ate (HR = 0.50; P < 0.001) and multivariate analysis (HR = 0.53; P = 0.001). Patients with
methylated MGMT promoters and high APNG expression demonstrated better OS, than
patients with methylated MGMT promoters and low APNG expression (HR = 0.59; P =
0.08). Retesting the cohort using IF showed similar results in both univariate (HR = 0.61;
P = 0.002) and multivariate analysis (HR = 0.81; P = 0.2). The results were supported by
data from the TCGA database.
Conclusions
Using two different assays combined with quantitative image analysis excluding non-tumour
cells, APNG was an independent prognostic factor among patients with a methylated
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Introduction
Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in
adults. The prognosis has improved from a median survival of 12.1 months with surgery and
radiotherapy alone to 14.6 months with today’s standard treatment, which includes concomi-
tant and adjuvant temozolomide (TMZ) [1–3]. Additional groups [4–8] have reported that
patients with a methylated MGMT promoter benefit more from treatment with TMZ than
patients with an un-methylated promoter, especially in the elderly GBM patients [9, 10]. How-
ever, some patients with methylated MGMT status do not respond to TMZ therapy, indicating
that MGMT status alone is not responsible for resistance towards TMZ in patients with GBMs.
Other mechanisms have been investigated, and studies suggest that alkylpurine-DNA-N-gly-
cosylase (APNG), also known as DNA methylpurine-N-glycosylase (MPG), can sensitize sev-
eral types of cancer cells towards TMZ [11, 12].
APNG, a DNA repair enzyme, is part of the base excision repair (BER) system, which
repairs the N3-methyladenine and N7-methylguanine adducts created by alkylating chemo-
therapeutic agents [13–15]. These methylations are the most abundant cytotoxic lesions pro-
duced by chemotherapeutics such as TMZ and comprise approximately 80% of the adducts
[15–17]. Previously, APNG has shown promising potential as a predictive [3] and prognostic
[18] marker in patients with GBMs. Agnihotri et al. used several in vitro assays as well as a
GBM xenograft model and showed that loss of APNG sensitizes cells to TMZ. Subsequently,
the authors performed an immunohistochemical (IHC) analysis of APNG in 244 GBM speci-
mens by including several sample sets [3]. For each cohort, patients were dichotomized into a
positive and a negative population, and univariate analyses were performed. In a large group
of patients treated with radiotherapy alone, APNG was not associated with overall survival
(OS). However; in the EORTC-NCIC cohort a median OS of 12 months was found for APNG-
positive patients compared to 16 months for APNG-negative patients [3]. Liu et al analyzed
the expression of APNG in 128 glioma patients using IHC and showed that the survival rate
was significantly shorter for glioma patients with positive APNG than for those with a negative
APNG status [18]. Based on these studies, APNG appeared to be an important biomarker in
GBM patients treated with TMZ.
The aim of this study was to investigate the association between OS and APNG status in
a retrospective well annotated patient cohort. Further, the level of APNG was examined
using=both a quantitative immunofluorescence (IF) method used previously in our lab
[19, 20], and the new method of dot technique in quantitative immunohistochemistry
(qIHC) [21]. qIHC is a novel methodology developed by DAKO, which combined with
image analysis, allows for quantitation of the expression of proteins in paraffin embedded
tissue samples using bright field assessments [22]. The current IF method has previously
been used successfully in other biomarker studies on the same cohort [19, 20]. In the present
study both qIHC and the IF techniques were further developed in order to identify both
tumor- and non-tumor cells. Exclusion of non-tumor cells removed any non-tumor APNG
contribution, and hence the cellular heterogeneity of GBMs was taken into account and
excluded from the analysis.
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Methods
Ethics
The official Danish ethical review board named the Regional Scientific Ethical Committee of
the Region of Southern Demark approved the use of human glioma tissue (permission J. No.
S-2011 0022) in the current study.
Patient material
Patients from the Region of Southern Denmark, who were diagnosed with a primary glioma
between 1 January 2005 and 31 December 2009, were included in the population-based cohort.
The material used is well-described and investigated in several studies [19, 20, 23–25].
A total of 242 patients had sufficient viable tissue for further analysis. In the qIHC assay five
sections were subsequently excluded due to small amounts of tumor tissue. Of the samples
included, 3 were WHO grade I, 23 WHO grade II, 25 WHO grade III and 186 WHO grade IV.
In the IF assay 19 tumor samples were excluded due to technical challenges, mainly unspecific
staining. The remaining 223 tumor samples were as follows: 3 WHO grade I, 21 WHO grade
II, 21 WHO grade III, and 178 WHO grade IV tumors. Tumor samples were classified by two
neuropathologists in accordance with the WHO classification of tumors of the central nervous
system [26]. Patient characteristics are described in Table 1.
We used data from two different cohorts generated by the TCGA Research Network
(http://cancergenome.nih.gov/) for supplementary analysis on mRNA APNG. Information
regarding APNG, based on the level of mRNA, age, gender, IDH1 and MGMT status were
obtained. Data in the first cohort was derived from RNA sequencing analyses [27], and a total
of 620 patients were identified; of these 226 were WHO grade II gliomas, 244 were WHO
grade III and 150 were GBMs. This cohort was used for comparison of the APNG mRNA level
between the different WHO grades only. Data in the other cohort was generated using Affyme-
trix U133A [28], and a total of 497 patients with WHO grade IV tumors were identified. This
Table 1. Patient characteristics.
WHO Grade II WHO Grade III WHO Grade IV
qIHC IF qIHC IF qIHC IF
n (%) n (%) n (%) n (%) n (%) n (%)
Subjects 23 (10) 21 (10) 25 (11) 21 (10) 186 (79) 178 (80)
Age (median) 46 46 58 58 65 65
Gender
Male 13 (57) 12 (57) 18 (72) 15 (71) 108 (58) 102 (57)
Female 10 (43) 9 (43) 7 (28) 6 (29) 78 (42) 6 (43)
PS
0–1 18 (78) 15 (71) 19 (76) 16 (76) 117 (63) 110 (62)
2–4 5 (22) 6 (29) 6 (24) 5 (24) 69 (37) 68 (38)
APNG
dots/cell 0.32 0.42 0.31
AF 0.50 0.67 0.69
Dead 14 (61) 12 (57) 23 (92) 19 (90) 177 (95) 170 (95)
OS (months) 58 58 14 21 10 10
Abbreviations: PS ECOG performance status; AF area fraction; qIHC quantitative immunohistochemistry; IF immunofluorescence
https://doi.org/10.1371/journal.pone.0178693.t001
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cohort was used for multivariate analysis. Both cohorts have been described previously [27,
28], brief patient characteristics are shown in S1 and S2 Tables.
Immunohistochemistry
For the qIHC assay, sections from FFPE tissues were stained using qIHC and the Dako EnVi-
sionTM+ system (Dako, Glostrup, Denmark). All stainings were performed at Dako Denmark.
Slides were de-paraffinized via baths of 2x5 min xylene, 2x2 min 96% ethanol, 2x2 min 70%
ethanol and finally transferred to demineralized water. Target retrieval was performed in a
buffer of 5 mM Na-Hepes, pH 8.0, at 97˚C for 20 min, in a Dako PT-link module. To block
endogenous peroxidase the sections were treated with Dako blocking reagent with additive.
Endogenous peroxidase block was performed initially (10 min) and after qIHC precipitation
reaction (20 min). Automated staining was performed on an Autostainer Link 48 (Dako).
Monoclonal rabbit anti-APNG (Abcam clone ab55461) (1:5000) was used as primary antibody
for qIHC (20 min). A cocktail of CD31 (M0823 (Dako), Clone JC70A) (1:30), CD45 (M0701
(Dako), Clones 2B11 + PD7/26) (1:75) and Iba1 (Wako Cat. #019–19741) (1:8000) antibodies,
which identify endothelial cells, leukocytes, and microglia was used as primary antibodies for
standard IHC/3’3-diaminobenzidine tetra-hydrochloride (DAB) EnVision Flex staining (20
min). qIHC staining was performed as described previously [22]. Conceptually, a polyclonal
goat anti-rabbit antibody conjugated to horseradish peroxidase (HRP) was used as secondary
antibody. Polyclonal rabbit anti-fluorescein isothiocyanate (FITC) conjugated to calf intestine
alkaline phosphatase (CIP) was used as tertiary conjugate to produce colored liquid permanent
red (LPR) dots for bright field microscopy. IHC staining with Dako Envision Flex+ Mouse
linker system was performed according to manufacturer’s instructions. In short, sections were
incubated with Dako EnVisionTM FLEX+ mouse linker for 15 minutes followed by incuba-
tion with Dako EnVisionTM FLEX/HRP for an additional 20 minutes. For visualization of
staining, the sections were treated with DAB. Finally, slides were counterstained with haema-
toxylin, rinsed with water, dehydrated in 99.9% ethanol and cover slipped with Sakura Tissue-
Tek Film Coverslipper.
Double fluorescence immunohistochemistry was performed on the Dako Autostainer plus
platform (DAKO Denmark A/S, Glostrup Denmark) in the Department of Pathology, Odense
University Hospital. Sections were dewaxed with xylene and rehydrated with ethanol. Heat
epitope retrieval (HIER) was performed using a microwave oven in TEG-buffer for 15 minutes
at 100˚C. Endogen peroxidase activity was blocked/reduced with 5-minute incubation in
hydrogen peroxidase. The sections were incubated with the primary antibody, monoclonal
mouse anti-APNG antibody (Abcam clone ab55461), at a dilution of 1:12000. Detection was
performed using DAKO CSA II, Biotin-Free Catalyzed Amplification System. A second HIER
was performed, as well as a second blocking of endogen peroxidase with hydrogen peroxide.
The sections were then incubated with a triple-cocktail consisting of antibodies against CD31
(M0823 (Dako), Clone JC70A) (1:50), CD45 (M0701 (Dako), Clones 2B11 + PD7/26) (1:1600)
and Iba1 (Wako Cat. #019–19741) (1:12000). Detection was performed using Perkin Elmer
TSATM, Plus Cyanine 5 System. Nuclear counterstaining was performed using VECTA-
SHIELD Mounting Medium containing DAPI.
Regarding both qIHC and IF, the stainings were compared with conventional chromogenic
IHC stainings to ensure specific reaction patterns.
Image analysis
For qIHC all slides were scanned using an Aperio Scanscope CS system (Aperio Technologies
Inc., Vista, CA, USA), at 20x magnification level. All images were analyzed using the Aperio
APNG as a prognostic marker in glioblastoma
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Genie pattern recognition. The system was trained to identify 3 different categories based on
morphology: Empty glass, tumor and normal tissue, enabling the Genie algorithm to distin-
guish between the three. The Genie Algorithm was trained by an experienced assessor using a
test-set consisting of 20 gliomas. To increase the precision of the analyzing tool, the test-set
was trained for 25,000 iterations. Tumor tissue identified by the Genie pattern recognition tool
was analyzed using the Indicalab ISH algorithm v. 1.2 (IndicaLab, Corrales, NM, USA). The
sensitivity of the algorithm was fine-tuned by comparing qIHC slides with conventional IHC
slides. All slides were evaluated in the Aperio ImageScope software (Aperio Technologies Inc.,
Vista, CA, USA) by a trained observer and reviewed by a certified neuropathologist prior to
analysis. This enabled visual assessment of each individual slide, as well as exclusion of prede-
fined areas from analysis based on the following exclusion criteria: 1) low cellularity, 2) necro-
sis, 3) larger vessels 4) artifacts. Remaining areas were labeled as regions of interest (ROI) and
included in the analysis. Classification of areas within ROIs was based on recognition of the
nuclear haematoxylin stain and exclusion of non-tumor cells exhibiting DAB positivity.
APNG protein expression was visualized as individual red chromogenic dots, each represent-
ing a predefined amount of protein determined during assay development. Only APNG pro-
tein expression in nuclei was included. This was determined by the distance of dots to nuclei
and was set to include only dots within or with minimal distance to nuclei borders. The num-
ber of dots per cell and a mean dots/cell was calculated for each slide.
For IF all images were obtained using a Leica DM6000B epifluorescense microscope, with
an Olympus DM72 1.4 Mega Pixel (1024 x 1360) high sensitivity CCD camera. Images were
classified based on the RGB three color model, and for each pixel the intensity threshold of
three different colors, red, green, and blue, was defined in the Visiomorph™ software module
(Visiopharm, Hørsholm, Denmark). Then uniform random sampling (meander fraction
based) was performed at 20x magnification as follows. Initially a bright-field image was taken
of the stained tumor sections at 1.25x magnification. Subsequently the ROI’s were manually
outlined and the sampling performed. The exclusion criteria were the same as for qIHC; addi-
tionally the images had to be well-exposed with limited unspecific background staining in all
of the three color bands. It was pre-defined that a minimum of 6 images should be available
for each tumor, or the tumor would be excluded from the analysis. An initial sampling fraction
between 5% and 30% was therefore used depending on area of tumor tissue. Exposure time for
DAPI and Cy5 were the same for all six staining-runs. Exposure time for FITC was calibrated
to avoid staining-run variation for APNG as previously described [3]. Areas with non-tumor
cells were excluded using the triple-cocktail leaving only tumor cells for further evaluation.
APNG positive nuclear areas were then defined as areas with intensity higher than the defined
threshold identifying positive staining, and based on the DAPI staining APNG positive and
negative nuclear areas were identified. Outcome variables were area fraction of APNG-positive
tumor cell nuclei (AF) and mean intensity of APNG in tumor cell nuclei (MI). A certified neu-
ropathologist was responsible for the fluorescence exposure and the training of the image anal-
ysis software. The training was performed on multiple images.
Statistical analysis
Data was described using frequency tables. Correlation between IDH1 status, APNG and sur-
vival was investigated using t-test. Median APNG protein expression was used as pre-defined
cutoff values. Patients with WHO grade I tumors were excluded from analyses due to the lim-
ited number of patients, thus 234 (qIHC) and 220 (IF) patients were included in the final anal-
yses. Overall survival, being defined as the time from primary surgery until death or censoring
(November 2014) was represented by Kaplan-Meyer curves. The survival functions were
APNG as a prognostic marker in glioblastoma
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analyzed for differences by the log-rank test. Cox proportional hazard regression analyses were
performed for patients with GBM. Only clinical variables which previously have been reported
to be prognostic in this cohort were included [23]. Optimal cutoff analyses were carried out as
described in [20], and values confirmed using ROC curves. All analyses were performed in
STATA version 11 (StataCorp LP, College Station, Texas, USA) computer software.
Results
Staining patterns in qIHC
Chromogenic stains showed APNG staining as clear, red dots in both tumor and non-tumor
cells, and it was seen in all WHO grades, mainly in or in close proximity to nuclei. The few
dots observed outside of cells were automatically excluded in accordance with the analysis
algorithm. Exclusion markers in the triple cocktail containing CD31, CD45 and Iba-1 were
seen as conventional chromogenic brown staining in the cytoplasm and in the membrane. The
excluded non-tumor cells were frequently located around vessels and areas with necrosis or
bleeding (Fig 1).
Staining patterns in IF
Positive APNG-staining, represented as a green fluorescence staining, was observed in the
nuclei in all WHO grades. Nuclei were defined with a blue DAPI staining and labeling of endo-
thelial cells, macrophages and microglia was seen as a red fluorescence staining. APNG label-
ing in these non-tumor cells were automatically excluded in accordance with the analysis
algorithm (Fig 2).
APNG expression levels in WHO grade II tumors using qIHC
Median APNG expression level was 0.32 dots/cell (range 0.15–0.49) (Fig 3). No association
between APNG expression and OS was identified (HR = 1.05; P = 0.93). Median OS was 62.4
months in patients with low expression of APNG and 57.2 months in patients with high
expression. The prognostic significance of IDH1 was investigated. A total of 20 patients (80%)
had mutated IDH1 (mIDH1). When patients were divided based on APNG and IDH1 status,
no difference in OS was observed (P> 0.05).
APNG expression levels in WHO grade III tumors using qIHC
Median APNG expression level was 0.42 dots/cell (range 0.15–0.92) (Fig 3). A trend towards
better OS in patients with high APNG expression level was identified, median OS 21.4 months
as compared to patients with low APNG expression, median OS 8.1 months (HR = 0.82;
P = 0.67). When patients were divided based on APNG and IDH1 status, no difference in OS
was observed (P> 0.05).
APNG expression levels in WHO grade IV tumors using qIHC
Median APNG expression level was 0.31 dots/cell (range 0.099–0.96) (Fig 3) in the group of
patients with WHO grade IV tumors. This was not significantly different from the expression
in patients with WHO grade I, and II and III tumors (Fig 3). Using 0.31 as cutoff, a significant
worse OS was observed in patients with low APNG expression level compared to patients with
high expression (HR = 0.75; P = 0.02) (Fig 3). Median OS was 12.2 months in patients with
high APNG and 9.4 months in patients with low APNG expression.
An explorative optimal cutoff analysis was performed. In qIHC 0.24 dots/cell was identified
as the optimal cutoff, dividing patients into an APNG low (25% of the patients) and an APNG
APNG as a prognostic marker in glioblastoma
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high group (75% of the patients). Patients with high expression of APNG had improved OS
(HR = 0.50; P =< 0.001) (Fig 3). Similar results were seen in multivariate analysis adjusting
for the effects of age, performance status, tumor crossing midline, treatment and gender
(HR = 0.53; P = 0.001).
APNG expression levels in WHO grade II tumors using IF
In the group of WHO grade II tumors, median AF was 0.50 (range 0.0091–0.93) (Fig 3).
Patients with low AF had an improved survival; median OS 68.1 months compared to 56.3 in
Fig 1. Images of APNG staining in different tumor subtypes. APNG expression visualized using quantitative
immunohistochemistry (qIHC). Endothelial cells, leukocytes and microglia/macrophages were excluded using co-stainings. A,
C, E: APNG expression in the nuclei is visualized and quantified by the number of red dots. Non-tumor cells were stained with
DAB. IHC stainings were evaluated by 1) exclusion of non-tumor cells (DAB) and 2) visualization of APNG expression (red
dots) in the tumor cells. B, D, F: Non-tumor cells were automatically excluded and APNG analysis was applied on tumor cells;
nuclei are blue and APNG expression visualized as qIHC dots are orange. Scalebar: 100 μm.
https://doi.org/10.1371/journal.pone.0178693.g001
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patients with high AF (HR = 1.91; P = 0.27). When patients were divided based on APNG and
IDH1 status, no difference in OS was observed (P> 0.05).
APNG expression levels in WHO grade III tumors using IF
Median AF was 0.67 (range 0.036–0.98) (Fig 3). Patients with high AF had a poor outcome
(median OS 6.8 months) compared to patients with low AF (median OS 34.7 months)
(HR = 2.46; P = 0.09). When patients were divided based on APNG and IDH1 status, no differ-
ence in OS was observed (P> 0.05).
Fig 2. Staining of APNG and the corresponding processed images. APNG expression visualized using quantitative
immunofluorescence (IF). Endothelial cells, leukocytes and microglia/macrophages were excluded using co-stainings.
APNG negative (blue) and positive (green) nuclei were identified. Non-tumor cells are red. In B, D and F the image analysis
software identifies the cells as follows: APNG-positive tumor cell nuclei (green), APNG-negative tumor nuclei (blue), non-
tumor cell nuclei (white), extra-nuclear exclusion cocktail staining (pink), excluded nuclei (red and yellow) and background
(turquoise).
https://doi.org/10.1371/journal.pone.0178693.g002
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APNG expression levels in grade IV tumors using IF
Median AF of WHO grade IV tumors was 0.69 (range 0.0001–0.996) (Fig 3). This was higher
than the expression in patients with low-grade gliomas, but similar to the expression in
patients with WHO grade III tumors (Fig 3). Patients with high AF had the best outcome
(HR = 0.74; P = 0.05) with a median OS of 13.4 months (Fig 3). Patients with low AF had a
median OS of 8.7 months. In an explorative analysis dichotomizing at AF of 0.75 (61% of the
patients with low AF and 39% with high AF) was identified as the optimal cutoff (HR = 0.61;
P = 0.002) (Fig 3). When adjusting for the effect of clinical variables age, performance status,
tumor crossing midline, treatment and gender a similar trend was observed (HR = 0.81;
P = 0.24) (Table 2).
MGMT status and survival
When GBM patients were divided based on APNG (optimal cutoff) and MGMT status, a signif-
icant difference in OS was identified; patients with high APNG expression and methylated
MGMT promoter had a median OS of 19.8 months, and patients with low APNG expression
and a methylated MGMT promoter had a median OS of 11.2 months (P< 0.001). This was also
significant in multivariate analysis, where patients with high APNG expression and a methyl-
ated MGMT promoter demonstrated a better OS, than patients with low APNG expression and
a methylated MGMT promoter (HR = 0.59; P = 0.08). However, APNG expression was not
prognostic in patients with an un-methylated MGMT promoter (HR = 0.80; P = 0.37) (Fig 4).
Using IF similar results were obtained; median OS was 24.3 months in patients with
high APNG expression and methylated MGMT status and 11.3 months in patients with low
APNG and a non-methylated MGMT promoter (P< 0.001). A similar trend was found in
Fig 3. Box-plots and survival curves. Box-plots showing the level of APNG and survival curves for APNG qIHC (A+C+E) and IF (B+D+E).
qIHC: There is no difference between the expression in level in patients with WHO grade IV tumors and patients with WHO grade I, II, and III
(A). Divided at median APNG was prognostic (P = 0.02) (C). At optimal APNG cut point (25% vs 75% of the patients), HR improved
(P < 0.001) (E). IF: The expression in patients with WHO grade IV tumors was higher than the expression in patients with low-grade gliomas,
but similar to the expression in patients with WHO grade III tumors (B). Divided at median there was a trend towards APNG being prognostic
(P = 0.05) (D). At optimal APNG cut point (61% vs. 39% of the patients), APNG was a prognostic factor in univariate analysis (P = 0.002) (F).
https://doi.org/10.1371/journal.pone.0178693.g003
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multivariate analyses (HR = 0.64; P = 0.08). In patients with an un-methylated MGMT promo-
tor APNG was not prognostic (HR = 1.21; P = 0.42) (Fig 4).
APNG expression in the TCGA-database
In the WHO grade II-IV cohort the median levels of APNG mRNA were 9.43 (range 8.39–
11.38), 9.41 (range 8.27–11.81), and 9.63 (range 8.61–11.83) for patients with WHO grade II,
Table 2. Multivariate Cox regression analysis of APNG protein levels in glioblastomas including clinical parameters.
Variable Baseline model APNG qIHC APNG IF
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age 1.01 1.00–1.03 0.23 1.01 1.00–1.03 0.15 1.01 1.00–1.03 0.07
Gender
Female 1.00 1.00 1.00
Male 1.53 1.11–2.10 0.009 1.45 1.05–2.00 0.02 1.36 0.96–1.95 0.09
Performance status
0–1 1.00 1.00 1.00
2–4 2.58 1.72–3.88 0.001 2.61 1.74–3.92 0.001 1.22 1.04–1.44 0.02
Tumor crossing midline
No 1.00 1.00 1.00
Yes 1.43 0.88–2.30 0.15 1.27 0.79–2.04 0.33 1.02 0.56–1.85 0.95
Post-surgical treatment
Stupp 1.00 1.00 1.00
Palliative 1.75 1.21–2.53 0.003 1.52 1.04–2.24 0.03 1.77 1.22–2.58 0.003
None 12.5 6.80–22.9 0.001 12.9 7.00–23.8 0.001 14.4 7.54–27.6 0.001
APNG
Low - - - 1.00 1.00
High 0.53 0.36–0.77 0.001 0.81 0.57–1.15 0.24
Abbreviations: qIHC quantitative immunohistochemistry; IF immunofluorescence. APNG low/high according to optimal cut point.
https://doi.org/10.1371/journal.pone.0178693.t002
Fig 4. Survival curves based on APNG and MGMT status. Median survival in patients with low APNG and methylated MGMT promoter was
2.8/6.1 months (qIHC/IF) compared to 4.5/11.3 months in patients with low APNG expression and a un-methylated MGMT promoter. Patients
with high APNG expression and un-methylated MGMT promoter had a median overall survival of 9.8/9.6 months whereas patients with high
APNG expression and methylated MGMT promoter (H/M) had a median overall survival of 20.3/20.3 months (P < 0.001). In multivariate
analysis patients with high APNG expression and methylated MGMT promoter demonstrated a better overall survival than patients with low
APNG expression and methylated MGMT promoter; HR 0.55, P = 0.04 (qIHC) and HR = 0.66, P = 0.1 (IF). Abbreviations: u-MGMT un-
methylated MGMT promoter, m-MGMT methylated MGMT promoter. APNG low/high was defined according to the optimal cut point, which
was for qIHC was 0.24 and for IF was 0.75.
https://doi.org/10.1371/journal.pone.0178693.g004
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III and IV tumors (Fig 5). The level of APNG mRNA was significantly higher in patients with
WHO grade IV tumors compared to patients with WHO grade II and III tumors (P< 0.001).
In the GBM cohort the median level of APNG mRNA was 7.32 (6.10–9.07). The level of
APNG mRNA was not associated with OS when divided at the median (HR = 0.90; P = 0.27)
or at the optimal cutoff for qIHC (25% of the patients with the lowest APNG vs. the 75% of the
patients with the highest APNG level) (HR = 1.00; P = 1.00). However; when divided at the
optimal cutoff for IF (61% of the patients with low APNG vs. the 39% with high APNG), a
trend towards high APNG and improved OS (HR = 0.85; P = 0.10) was identified (Fig 5). For
all 3 cut points we performed a multivariate analysis including age, gender and MGMT status,
which indicated a better survival in patients with high levels of APNG mRNA, but this was not
significant (S3 Table).
Fig 5. Box-plot and survival curves for patients in the TCGA data set. The level of APNG mRNA was significantly higher in patients with
WHO grade IV tumors compared to patients with WHO grade II and III tumors (A). When patients were divided at the median (B) or at the
optimal cut point for qIHC (25% of the patients with the lowest APNG vs. the 75% of the patients with the highest APNG level) (C), APNG
mRNA was not associated with overall survival. When divided at the optimal cut point for IF (61% of the patients with low APNG vs. the 39%
with high APNG), a trend towards high APNG and improved overall survival (HR = 0.85; P = 0.10) was identified (D).
https://doi.org/10.1371/journal.pone.0178693.g005
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Discussion
This is the first study to investigate the prognostic value of APNG with both qIHC and quanti-
tative IF in GBMs with simultaneous exclusion of APNG expression in non-tumor cells. We
demonstrated that GBM patients with high APNG expression had an improved OS compared
to patients with low expression. This was shown in univariate analysis and was confirmed in
multivariate analysis in the qIHC assay. Statistical significance was, however, only observed in
univariate and not in multivariate analysis using IF. When dichotomizing patients into high-
and low expressers with an optimal cutoff, a significant association between OS and APNG
was found in both assays. No statistically significant association between APNG-expression
and OS in patients with WHO grade II and III tumors was observed, probably due to the
small number of patients. Surprisingly: in patients with WHO grade III tumors the IF assay
revealed a trend towards improved OS in patients with low APNG expression. This is in con-
trast to the other results. However, the analysis included only few patients, which may influ-
ence the results.
Using qIHC, APNG expression was higher for WHO grade III tumors than for both WHO
grade II and grade IV tumors. This was in contrast to our results obtained using IF as well as
TCGA data and the study by Liu et al [18]. The higher levels in grade III tumors observed
using qIHC may be caused by the high levels observed in the few anaplastic oligodendroglio-
mas. Some of these patients were excluded from the IF analysis due to technical errors. As the
number of patients in our analysis was small, exclusion of even few patients, especially patients
with very high levels of APNG, may influence the results significantly. This may explain the
conflicting results in patients with WHO grade III tumors, where nearly 20% of the patients in
the qIHC analyses were excluded from the IF approach. Moreover, differences in the sensitiv-
ity of the two assays used in our study may influence the results. Accordingly, the sensitivity of
the IF approach may be higher in terms of detecting high grade tumors with high APNG pro-
tein levels. This needs validation in a larger cohort.
Using both qIHC and IF, tumors with the same WHO grade had large differences in APNG
expression levels. This is in accordance with observations made by others, where e.g. APNG
mRNA levels are reported to vary up to tenfold between GBMs [29]. This is not only true for
APNG. In the clinical setting MGMT is often categorized as positive or negative, however,
MGMT has been reported to exhibit varying levels of expression within the same WHO grade
[30–32]. The different expression levels illustrates the highly heterogeneous nature of gliomas,
GBMs especially, and support the need for more individualized approaches [33].
For patients with WHO grades II and III tumors, differences in OS were observed when
dichotomizing at the median expression, favoring patients with high expression, except for
patients with WHO grade III tumors when using IF. This trend towards improved survival
is supported by the results for WHO grade IV. The relatively small patient groups of lower
grade tumors might contribute to the lack of statistical significance, and a larger patient
group is required to further evaluate the prognostic value of APNG in WHO grade II and III
tumors. As IDH1 has been shown to be prognostic in patients with WHO grade II and III
tumors, we investigated if the combined information of APNG and IDH1 in these patients
was prognostic. This was not confirmed, probably due to the limited number of patients in
each group.
In the largest patient group of WHO grade IV tumors, we found a significant association
between high levels of APNG and better OS when adjusting for clinical parameters as well as
MGMT status. All though based on mRNA, the results were supported by the results from the
TCGA dataset which indicate a similar trend in a multivariate analysis when using the cutoff
from the IF assay. Moreover our results are in line with results obtained in in vitro studies [29,
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34], where high APNG levels were associated with increased sensitivity to treatment. However,
this is in contrast to the study of Liu et al. showing that patients with no APNG expression had
the most favorable outcome [18]. Results from that study should, however, be interpreted with
caution since all glioma grades were combined into one analysis, and as it was demonstrated
in our study, high grade gliomas expressed higher APNG levels than low grade gliomas. Our
study is the first to exclude APNG expression in non-tumor cells from the analysis. The ratio-
nale for doing so is “false positive” staining in non-neoplastic cells influencing the measure-
ments. This may also contribute to the discrepancy between our study and the study by Liu
et al. In the study by Agnihotri et al., 244 GBMs were separated as being APNG-negative and
APNG-positive using conventional IHC. However, different results were obtained in their
study as high expression of APNG was associated with poor OS in some of the cohorts
while there was no difference in OS in other cohorts [3]. Moreover, no multivariate analyses
were reported. Using the categories “positive” and “negative” only, instead of continuous
quantitative measurements may be an important explanation for the different results obtained,
as the cutoffs might differ between the studies.
In our study no tumors were APNG-negative. This might be due to the high sensitivity of
both of our methods and suggests a need for differentiation between expression levels. Another
parameter, which may influence the results obtained in different studies, is the amount of tis-
sue analyzed for each tumor. We used whole slides and observed large intra-tumoral variation
in APNG expression. Therefore we excluded patients with small amounts of tissue. In the
study by Agnihotri et al., tissue micro-arrays were used, and the individual cores were catego-
rized as “positive” and “negative” [3]. Previous studies have shown that tissue micro-arrays
should be used with caution [35, 36], and the use of tissue micro-arrays could possibly explain
the difference between our results and the results obtained by Agnihotri et al. Discrepancy
between the different studies may also be influenced by different antibody clones used. Several
different clones have been used in APNG studies, and only Liu et al. used the same clone as the
one used in our study (Abcam clone ab55461). To minimize the degree of uncertainty associ-
ated with different clones further studies are needed.
Based on the supposed function of APNG as a part of the BER system, it seems probable that
a lack of this enzyme would confer poorer resistance towards alkylating agents inducing N3-
and N7 lesions to the DNA. A previous study has shown that destabilization of the BER system
confers increased sensitivity towards alkylating agents in human breast cancer cells [12]. The
BER system appears to be sensitive to high amounts of its critical enzymes. Thus, overexpression
of molecules in one part of the system might influence the subsequent steps, which no longer
can cope with the increased amount of substrate. High expression of APNG may cause this
destabilization, which is explained by a downstream shift of the rate limiting step of the system.
High numbers of DNA alkylations being handled by a high level of APNG accordingly puts
pressure on the downstream enzymes of the BER system. The critical enzyme, Polymerase β,
can become over-saturated and give rise to an increased amount of cytotoxic 5’dRP intermedi-
ates [12, 13]. It has been suggested that these cytotoxic lesions, which may be more toxic than
the original lesions, lead to apoptosis of tumor cells, thereby resulting in an improved patient OS
[15]. Our protein data and to some extent the TCGA data are in line with these aspects of the
APNG biology, as high APNG protein and mRNA levels were associated with improved OS. In
a related study on ovarian cancer cell lines, the authors found that cells expressing high levels of
APNG had an increased sensitivity towards TMZ. This suggests that the BER system is a critical
system in terms of survival of tumor cells exposed to alkylating agents [11]. It may be speculated
if APNG expression does not influence survival when MGMT is expressed in GBM patients
with unmethylated promoters, and that the O6-adducts repaired by MGMT are more cytotoxic
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than the N-alkylations repaired by APNG [37]. This may explain why our results indicate that
the significance of the BER system appear higher in MGMT promoter-methylated GBMs.
In conclusion APNG measured by qIHC was found to be a significant independent prog-
nostic factor for OS in patients with GBMs. This was supported by IF measurements. The
quantitative approach combined with exclusion of APNG expression in non-tumor cells in
both assays have contributed to a more exact analysis of the tumor-specific expression. We
expect that APNG qIHC can potentially identify GBM patients who will not benefit from treat-
ment with TMZ.
Supporting information
S1 Table. Patient characteristics in the TCGA dataset. Patient characteristics for the 620
patients evaluated by RNA sequencing analyses.
(DOCX)
S2 Table. Patient characteristics in the TCGA GBM dataset. Patient characteristics for the
497 GBM patients in whom APNG status was generated using Affymetrix.
(DOCX)
S3 Table. Multivariate analyses based on the TCGA GBM dataset.
(DOCX)
Acknowledgments
We acknowledge the technical work done by Anne Bruun, Marianne Marcussen, Helle Wohl-
leben and Tanja Dreehsen Højgaard. The study was supported by the Danish Cancer Society.
Part of this study is based upon data generated by the TCGA Research Network: http://
cancergenome.nih.gov/.
Author Contributions
Conceptualization: KLJ HD JL BWK.
Data curation: SF S. Hellwege RD KLJ HD MDS BWK.
Formal analysis: SF S. Hellwege RD KLJ JL MDS.
Funding acquisition: HD BWK.
Investigation: SF S. Hellwege RD KLJ JL MDS.
Methodology: SF S. Hellwege RD KLJ HD JL MDS S. Hansen BWK.
Project administration: HD BWK.
Resources: HD BWK.
Software: SF S. Hellwege RD KLJ BWK.
Supervision: RD KLJ HD BWK.
Validation: SF S. Hellwege RD KLJ HD JL MDS S. Hansen BWK.
Visualization: SF S. Hellwege RD KLJ.
Writing – original draft: SF S. Hellwege RD.
Writing – review & editing: RD KLJ HD JL MDS S. Hansen BWK.
APNG as a prognostic marker in glioblastoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178693 June 29, 2017 14 / 17
References
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus con-
comitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987–96. https://
doi.org/10.1056/NEJMoa043330 PMID: 15758009
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiother-
apy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology. 2009;
10(5):459–66. https://doi.org/10.1016/S1470-2045(09)70025-7 PMID: 19269895
3. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, et al. Alkylpurine-DNA-N-gly-
cosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is
associated with poor survival in patients. The Journal of clinical investigation. 2012; 122(1):253–66.
Epub 2011/12/14. https://doi.org/10.1172/JCI59334 PMID: 22156195;
4. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, et al. Correlation between O6-methyl-
guanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients
treated with neoadjuvant temozolomide. Journal of clinical oncology: official journal of the American
Society of Clinical Oncology. 2007; 25(12):1470–5. Epub 2007/04/20. https://doi.org/10.1200/jco.2006.
07.4807 PMID: 17442989.
5. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, et al. Combined analysis of O6-methylgua-
nine-DNA methyltransferase protein expression and promoter methylation provides optimized prognos-
tication of glioblastoma outcome. Neuro-oncology. 2013; 15(3):370–81. https://doi.org/10.1093/
neuonc/nos308 PMID: 23328811;
6. Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T. Prognostic significance of the immuno-
histochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug
resistance protein-1 in glioblastomas. Neuropathology: official journal of the Japanese Society of Neuro-
pathology. 2009; 29(4):379–88. https://doi.org/10.1111/j.1440-1789.2008.00983.x PMID: 19019175.
7. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, et al. Comparative
assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequen-
cing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methyl-
guanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012; 118(17):4201–
11. Epub 2012/02/02. https://doi.org/10.1002/cncr.27392 PMID: 22294349.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and
benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005; 352(10):997–
1003. Epub 2005/03/11. https://doi.org/10.1056/NEJMoa043331 PMID: 15758010.
9. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus
standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with
glioblastoma: the Nordic randomised, phase 3 trial. The lancet oncology. 2012; 13(9):916–26. https://
doi.org/10.1016/S1470-2045(12)70265-6 PMID: 22877848.
10. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy
alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised,
phase 3 trial. The lancet oncology. 2012; 13(7):707–15. Epub 2012/05/15. https://doi.org/10.1016/
S1470-2045(12)70164-X PMID: 22578793.
11. Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer
cells to alkylating agent temozolomide. Clin Cancer Res. 2007; 13(1):260–7. Epub 2007/01/04. https://
doi.org/10.1158/1078-0432.CCR-06-1920 PMID: 17200364.
12. Trivedi RN, Wang XH, Jelezcova E, Goellner EM, Tang JB, Sobol RW. Human methyl purine DNA gly-
cosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Molecu-
lar pharmacology. 2008; 74(2):505–16. Epub 2008/05/15. https://doi.org/10.1124/mol.108.045112
PMID: 18477668;
13. Bobola MS, Kolstoe DD, Blank A, Chamberlain MC, Silber JR. Repair of 3-methyladenine and abasic
sites by base excision repair mediates glioblastoma resistance to temozolomide. Frontiers in oncology.
2012; 2:176. Epub 2012/12/12. https://doi.org/10.3389/fonc.2012.00176 PMID: 23230562;
14. Engelward BP, Dreslin A, Christensen J, Huszar D, Kurahara C, Samson L. Repair-deficient 3-methyla-
denine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-
induced chromosome damage and cell killing. The EMBO journal. 1996; 15(4):945–52. PMID:
8631315;
15. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating
agents. Nature reviews Cancer. 2012; 12(2):104–20. Epub 2012/01/13. https://doi.org/10.1038/
nrc3185 PMID: 22237395;
APNG as a prognostic marker in glioblastoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178693 June 29, 2017 15 / 17
16. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investiga-
tion of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.
Biochemistry. 1994; 33(31):9045–51. Epub 1994/08/09. PMID: 8049205.
17. Smith SA, Engelward BP. In vivo repair of methylation damage in Aag 3-methyladenine DNA glycosy-
lase null mouse cells. Nucleic acids research. 2000; 28(17):3294–300. PMID: 10954597;
18. Liu C, Tu Y, Yuan J, Mao X, He S, Wang L, et al. Aberrant expression of N-methylpurine-DNA glycosy-
lase influences patient survival in malignant gliomas. Journal of biomedicine & biotechnology. 2012;
2012:760679. Epub 2012/04/13. https://doi.org/10.1155/2012/760679 PMID: 22496614;
19. Dahlrot RH, Hansen S, Jensen SS, Schroder HD, Hjelmborg J, Kristensen BW. Clinical value of CD133
and nestin in patients with glioma: a population-based study. International journal of clinical and experi-
mental pathology. 2014; 7(7):3739–51. Epub 2014/08/15. PMID: 25120750;
20. Dahlrot RH, Hansen S, Herrstedt J, Schroder HD, Hjelmborg J, Kristensen BW. Prognostic value of
Musashi-1 in gliomas. Journal of neuro-oncology. 2013; 115(3):453–61. Epub 2013/09/24. https://doi.
org/10.1007/s11060-013-1246-8 PMID: 24057325.
21. Jensen K, Krusenstjerna-Hafstrom R, Lohse J, Petersen KH, Derand H. A novel quantitative immuno-
histochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded
specimens: analytical performance measuring HER2. Modern pathology: an official journal of the United
States and Canadian Academy of Pathology, Inc. 2016. Epub 2016/10/22. https://doi.org/10.1038/
modpathol.2016.176 PMID: 27767098.
22. Lohse J, Petersen KH, Woller NC, Pedersen HC, Skladtchikova G, Jorgensen RM. Improved Catalyzed
Reporter Deposition, iCARD. Bioconjugate chemistry. 2014; 25(6):1036–42. https://doi.org/10.1021/
bc400311g PMID: 24852797.
23. Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J, Hansen S. A population-based study of high-
grade gliomas and mutated isocitrate dehydrogenase 1. International journal of clinical and experimen-
tal pathology. 2013; 6(1):31–40. Epub 2012/12/14. PMID: 23236540;
24. Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J, Hansen S. A population-based study of low-
grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). Journal of neuro-oncology. 2013; 114
(3):309–17. Epub 2013/07/03. https://doi.org/10.1007/s11060-013-1186-3 PMID: 23817809.
25. Music D, Dahlrot RH, Hermansen SK, Hjelmborg J, de Stricker K, Hansen S, et al. Expression and prog-
nostic value of the WEE1 kinase in gliomas. Journal of neuro-oncology. 2016. Epub 2016/01/08. https://
doi.org/10.1007/s11060-015-2050-4 PMID: 26738845.
26. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Ner-
vous System2007.
27. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular Profiling
Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164
(3):550–63. Epub 2016/01/30. https://doi.org/10.1016/j.cell.2015.12.028 PMID: 26824661;
28. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblas-
toma genes and core pathways. Nature. 2008; 455(7216):1061–8. Epub 2008/09/06. https://doi.org/10.
1038/nature07385 PMID: 18772890;
29. Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, et al. N-methylpurine DNA glycosylase
and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro-
oncology. 2011; 13(5):471–86. https://doi.org/10.1093/neuonc/nor011 PMID: 21377995;
30. Bobola MS, Berger MS, Ellenbogen RG, Roberts TS, Geyer JR, Silber JR. O6-Methylguanine-DNA
methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. Clini-
cal cancer research: an official journal of the American Association for Cancer Research. 2001; 7
(3):613–9. PMID: 11297257.
31. Andersson U, Malmer B, Bergenheim AT, Brannstrom T, Henriksson R. Heterogeneity in the expres-
sion of markers for drug resistance in brain tumors. Clinical neuropathology. 2004; 23(1):21–7. Epub
2004/02/28. PMID: 14986930.
32. Araki Y, Mizoguchi M, Yoshimoto K, Shono T, Amano T, Nakamizo A, et al. Quantitative digital assess-
ment of MGMT immunohistochemical expression in glioblastoma tissue. Brain tumor pathology. 2011;
28(1):25–31. Epub 2011/01/21. https://doi.org/10.1007/s10014-010-0004-2 PMID: 21249460.
33. Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblas-
toma. Journal of neuro-oncology. 2012; 108(1):11–27. https://doi.org/10.1007/s11060-011-0793-0
PMID: 22270850;
34. Rinne ML, He Y, Pachkowski BF, Nakamura J, Kelley MR. N-methylpurine DNA glycosylase overex-
pression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts.
Nucleic acids research. 2005; 33(9):2859–67. https://doi.org/10.1093/nar/gki601 PMID: 15905475;
APNG as a prognostic marker in glioblastoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178693 June 29, 2017 16 / 17
35. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astro-
cytomas. Journal of neuro-oncology. 2008; 90(2):157–70. Epub 2008/07/10. https://doi.org/10.1007/
s11060-008-9648-8 PMID: 18612800.
36. Chiesa-Vottero AG, Rybicki LA, Prayson RA. Comparison of proliferation indices in glioblastoma multi-
forme by whole tissue section vs tissue microarray. American journal of clinical pathology. 2003; 120
(6):902–8. Epub 2003/12/16. https://doi.org/10.1309/8UAU-KFK3-NBDM-VTNU PMID: 14671979.
37. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Cur-
rent molecular pharmacology. 2012; 5(1):102–14. PMID: 22122467.
APNG as a prognostic marker in glioblastoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0178693 June 29, 2017 17 / 17
